Carb-X secures USD 370m in fight against antibiotic resistance

International antibiotic alliance Carb-X has received commitments of up to USD 370m to accelerate the development of new antibiotics to combat a future shortage. The news is welcomed by several players on the AMR field.

Aleks Engel, a partner of Novo Holdings’s antimicrobial activities, the Repair Impact Fund | Photo: Novo Holdings / PR

International antibiotic alliance Carb-X has secured USD 370m to continue its fight against antibiotic-resistant bacteria, the nonprofit has announced in a news release.

The grant comes from a string of prominent players within the healthcare area, including the UK’s Wellcome Trust and the Biomedical Advanced Research and Development Authority (BARDA) in the US, which also participated in the funding the organization with a capital injection of USD 350m back when it launched in 2016.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs